Search Results
Dec 19, 2025, 03:00 ET The CHMP adopted a positive opinion for Vueway® (gadopiclenol) for its use in pediatric patients under 2 years of age
54(8):475-484.Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast
More news about: Bracco Group
Dec 18, 2025, 17:03 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Dec 18, 2025, 16:58 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Dec 18, 2025, 16:43 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Dec 18, 2025, 16:41 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Dec 18, 2025, 16:32 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Dec 18, 2025, 10:40 ET Neuraxpharm Goes Live with TraceLink MINT to Standardize Real‑Time Data Exchange Across Its Global Supply Chain Network
leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 35 years. Neuraxpharm is constantly innovating, with new products and solutions to
More news about: TraceLink Inc.
Dec 18, 2025, 10:22 ET Neuraxpharm Goes Live with TraceLink MINT to Standardize Real‑Time Data Exchange Across Its Global Supply Chain Network
leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 35 years. Neuraxpharm is constantly innovating, with new products and solutions to
More news about: TraceLink Inc.
Dec 18, 2025, 09:00 ET Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance
AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activitySACRAMENTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical
More news about: Lunai Bioworks Inc.
Dec 18, 2025, 08:05 ET Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Dec 17, 2025, 16:00 ET Cohen & Steers Infrastructure Fund, Inc. Declares Distributions for January, February, and March 2026
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)Symbol: (NYSE: UTF)
More news about: Cohen & Steers, Inc.
Dec 17, 2025, 11:30 ET New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
addictive behaviors.Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent
More news about: Indivior PLC
Dec 17, 2025, 02:00 ET KI-Optimierungstechnologie von Nota sorgt nach Erfolg im Nahen Osten die Verkehrsinnovation in Afrika voran
ITS-Technologie beschleunigt Expansion vom Nahen Osten nach AfrikaUnterzeichnung eines Technologie-Liefervertrags mit HANIL STM für das von LG CNS geleitete ITS-Projekt in NairobiSEOUL, Südkorea, 17. Dezember 2025
More news about: Nota AI
Dec 16, 2025, 17:36 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Declares Year-End Capital Gain Distribution
https://www.cohenandsteers.com/ Symbol: (NYSE: CNS)About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Dec 16, 2025, 17:34 ET Cohen & Steers Closed-End Funds Declare Distributions for January, February and March 2026
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Dec 16, 2025, 11:53 ET Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
systems are unlocking the broader $44 billion cell-based therapy opportunity by enabling off-the-shelf, scalable treatments for kidney disease, diabetes, CNS disorders, and cardiovascular conditions, creating an urgent window for investors to capture this industrial transformation[4].Avant
More news about: Equity Insider
Dec 16, 2025, 08:00 ET TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex
TSC Alliance, has invested in Aeovian Pharmaceuticals as part of their Series B financing in support of their Phase 2 trial of AV078, a first-in-class CNS-penetrant selective mTORC1 inhibitor in tuberous sclerosis complex (TSC).
More news about: TSC Alliance
Dec 16, 2025, 08:00 ET Nota AI Optimization Technology Drives Traffic Innovation in Africa, Following Success in the Middle East
accelerates expansion from Middle East to AfricaSigns technology supply contract with HANIL STM for the Nairobi ITS Project led by LG CNSSEOUL, South Korea, Dec. 16, 2025 /PRNewswire/ -- Nota AI (CEO Myungsu
More news about: Nota AI
Dec 16, 2025, 02:00 ET Nota AI Optimization Technology Drives Traffic Innovation in Africa, Following Success in the Middle East
accelerates expansion from Middle East to AfricaSigns technology supply contract with HANIL STM for the Nairobi ITS Project led by LG CNSSEOUL, South Korea, Dec. 16, 2025 /PRNewswire/ -- Nota AI (CEO Myungsu
More news about: Nota AI
Dec 15, 2025, 23:55 ET Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
orally at the 2025 ASCO Annual Meeting [1]. The results showed a CNS-ORR of 67.6%, a central nervous system clinical benefit rate (CNS-CBR) of 88.2%, and a median central nervous system progression-free survival (CNS-PFS) of 15 months. The results of another Phase II clinical study of utidelone
More news about: Biostar Pharma, Inc.
Dec 12, 2025, 08:35 ET Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Dec 11, 2025, 07:00 ET NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
medicinal chemistry aimed at developing first- or best-in-class treatments for major CNS disorders, from ALS to narcolepsy."The patent covers a broad family of compounds with potential applications in multiple CNS-related conditions, including narcolepsy, where dysregulation of orexin signalling
More news about: NewcelX Ltd.
Dec 11, 2025, 02:00 ET Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
medicine and Adasuve®, will be eliminated, delivering immediate cost savings and enhancing overall deal economics.In addition, two promising CNS pipeline assets targeting Parkinson's disease and Cyclic Vomiting Syndrome (CVS), both at Phase 2 clinical stage, will be integrated into the Company's
More news about: Lee's Pharmaceutical Holdings Limited
Dec 11, 2025, 02:00 ET Lee's Pharmaceutical Holdings Limited acquiert la plateforme et les actifs de Staccato® One Breath Technology®, renforçant ainsi l'expansion de son pipeline et faisant progresser son partenariat mondial avec UCB grâce aux droits acquis
permettra de réaliser des économies immédiates et d'améliorer l'économie globale de l'opération.En outre, deux actifs prometteurs du pipeline CNS ciblant la maladie de Parkinson et le syndrome des vomissements cycliques (SVC), tous deux au stade clinique de phase 2, seront intégrés au portefeuille
More news about: Lee's Pharmaceutical Holdings Limited
Dec 10, 2025, 15:30 ET Connected Nation's BEAD Tracker provides details for the nearly 4M locations to get broadband using $20B in federal funds
of high-speed internet both in your area and nationally. That includes tracking the technology type, providers awarded funds, and much more." CN's BEAD Tracker (
More news about: Connected Nation